Humanized antibodies to LIV-1 and use of same to treat cancer
USRE48959E1 · kind E1 · reissue
1Cited by
34References
124Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 4, 2018 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | Jan 4, 2038 |
Classification
- Technology area (CPC —)General
Abstract
The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.